Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: A single institution experience

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 529-533

  Kotteas, Elias ^a,b   Alamara, Christina ^a   Kiagia, Maria ^a   Pantazopoulos, Kosmas ^a   Boufas, Anastasios ^a   Provata, Aspasia ^a   Charpidou, Adrianni ^a   Syrigos, Konstantinos N ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bisphosphonates; Bone metastases; Non small cell lung cancer; Small cell lung cancer; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH CENTER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 40549112304     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Terpos E and Syrigos KN: Pathophysiology and Management of Bone Metastases in Lung Cancer. In: Tumors of the Chest, Biology, Diagnosis and Management. Syrigos KN, Nutting C and Roussos C (eds.). New York, Springer-Verlag, pp. 551-562, 2006.
2. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E and Seaman J: Zolendronic acid is superior to pamindronate in the treatment of hypercalcemia of malignancy: a pool analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001.
3. Heidenreich A and Ohlmann CH: Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev Anticancer Ther 4: 991-1005, 2004.
4. Pecherstorfer M: Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother 5: 2341-2350, 2004.
5. Berenson JR: Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10: 52-62, 2005.
6. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D and Seaman JJ: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150-3157, 2003.
7. World Health Organisation: Cancer Pain Relief. WHO Publications Center, Albany, New-York, 1986.
8. Cameron D: Patient management issues in metastatic bone disease. Semin Oncol 31: 79-82, 2004.
9. Kiagia M, Karapanagiotou E, Charpidou A Dilana K, Dionellis G, Dannos I, Georgiou E and Syrigos KN: Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 26: 3133-3136, 2006.
10. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J and Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12: 220-229, 1998.
11. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonates treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
12. Syrigos KN, Michalaki V, Mitromaras A, Pliarchopoulou F, Katirtzoglou N, Antonaki E and Roussou P: Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion. In Vivo 16: 361-364, 2002.